… ODD from FDA and pre-clinical data was presented at two scientific meetings. QR-313 is expected to enter the clinic … and Thaddeus (Ted) Dryja appointed to ProQR’s ScientificAdvisoryBoard (SAB). In vivo proof of concept data for novel Axiomer …
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
… and presented positive pre-clinical data at two European scientific conferences. WINGS, a Phase 1/2 safety and … Appointed several thought leaders to ScientificAdvisoryBoard (Drs. Phil Zamore, Cy Stein, Scott Armstrong and …
… A. de Boer, Founder and CEO, Gerard Platenburg, Chief Scientific Officer, and René Beukema, Chief Corporate … the University of California at Davis and ProQR ScientificAdvisoryBoard member will also present. In addition, the Company …